Dissection and thrombus were observed during use of the stellarex device.Additional intervention was required to treat the patient, thus resulted in a prolonged procedure.Stellarex 0.035 otw drug-coated angioplasty balloon, paclitaxel drug, 3.3 mg, therapy date: (b)(6) 2017, the stellarex balloon is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency.Lot #: fcw17c23a, expiration date: 04/19/2019, (b)(4).(b)(6).Pma number is not applicable.The device is commercial product with a ce mark./ combination product is applicable the device was disposed, thus no product evaluation was performed.Per the ifu, vessel dissection and thrombosis are listed as potential complications/adverse events of the procedure.
|